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Introduction: The variability in late toxicities among childhood cancer survivors (CCS) is only partially explained
by treatment and baseline patient characteristics. Inter-individual variability in the association between treat-
ment exposure and risk of late toxicity suggests that genetic variation possibly modiﬁes this association. We
reviewed the available literature on genetic susceptibility of late toxicity after childhood cancer treatment re-
lated to components of metabolic syndrome, bone mineral density, gonadal impairment and hearing impair-
ment.
Methods: A systematic literature search was performed, using Embase, Cochrane Library, Google Scholar,
MEDLINE, and Web of Science databases. Eligible publications included all English language reports of candi-
date gene studies and genome wide association studies (GWAS) that aimed to identify genetic risk factors as-
sociated with the four late toxicities, deﬁned as toxicity present after end of treatment.
Results: Twenty-seven articles were identiﬁed, including 26 candidate gene studies: metabolic syndrome
(n=6); BMD (n= 6); gonadal impairment (n= 2); hearing impairment (n= 12) and one GWAS (metabolic
syndrome). Eighty percent of the genetic studies on late toxicity after childhood cancer had relatively small
sample sizes (n < 200), leading to insuﬃcient power, and lacked adjustment for multiple comparisons. Only
four (4/26= 15%) candidate gene studies had their ﬁndings validated in independent replication cohorts as part
of their own report.
Conclusion: Genetic susceptibility associations are not consistent or not replicated and therefore, currently no
evidence-based recommendations can be made for hearing impairment, gonadal impairment, bone mineral
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density impairment and metabolic syndrome in CCS. To advance knowledge related to genetic variation inﬂu-
encing late toxicities among CCS, future studies need adequate power, independent cohorts for replication,
harmonization of disease outcomes and sample collections, and (international) collaboration.
1. Introduction
Survival rates after childhood cancer now approach 80% in devel-
oped countries as a result of enhanced stratiﬁcation, more eﬀective
treatment and optimized supportive care (Gatta et al., 2014). The in-
creasing number of childhood cancer survivors (CCS) has led to the
growing awareness of chronic health eﬀects resulting from treatment
for childhood cancer (Geenen et al., 2007; Oeﬃnger et al., 2006). Ex-
amples of long-term consequences include hearing impairment, gonadal
impairment and cardiotoxicity. The inter-individual variability in the
number and magnitude of health problems in similarly treated CCS
suggests that genetic variation modiﬁes the association between treat-
ment and risk of late toxicity.
To identify such genetic variants two common approaches have
been applied: a candidate gene approach, and more recently, the
genome wide association study (GWAS) approach. Candidate gene
studies focus on associations between genetic variation within pre-
speciﬁed genes of interest and speciﬁc outcomes, while GWASs are
hypothesis-free searches that can identify novel single-nucleotide
polymorphisms (SNPs) that potentially modify the risk of a late toxicity.
After completion of the Human Genome Project (HGP)
(HumanGenomeProject, 2015) in 2003 and the International HapMap
project, GWASs have discovered many thousands of genetic variants
associated with a variety of diseases (EMBL-EBI, 2017), which cata-
lyzed research on genetic variation underlying late toxicity among
cancer survivors (MacArthur et al., 2017). Except for cardiotoxicity
(Aminkeng et al., 2016a), the resulting number of genetic variation
studies in CCS have not produced unambiguous evidence in this ﬁeld.
The lack of strong evidence has impeded translation into clinical
practice, such as patient counseling or dose-reduction trials. In contrast,
genotyping of childhood cancer patients in order to risk-adapt treat-
ment based on risk models predicting susceptibility to speciﬁc toxicities
is expected to become standard of care. A comprehensive review of
genetic aspects of acute toxicity was recently published (Mapes et al.,
2017). However, a recent overview of genetic susceptibility studies
concerning late toxicities in CCS is not yet available.
An international collaboration is currently working on the identiﬁ-
cation of genetic determinants associated with hearing impairment and
female gonadal impairment, in a large cohort of CCS (European Union’s
Seventh Framework programme project PanCareLIFE). In the current
study, we summarize the results of a systematic literature search and
evaluate the results and quality of available literature on genetic sus-
ceptibility of these two late toxicities (hearing impairment and female
gonadal impairment) and three hormone-related late toxicities (male
Fig. 1. Flowchart study selection process Review Genetics of Late Eﬀects.
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gonadal impairment, metabolic risk factors and bone mineral density
impairment).
2. Methods
2.1. Search strategy
To provide an overview of the established genetic susceptibility
factors associated with late toxicities in childhood cancer survivors, we
identiﬁed relevant articles, published up until September 2017, by
systematically searching Embase, Cochrane, Google Scholar, MEDLINE
and Web of science. Details of the full search strategy for each database
are included in Appendix I. The computer-based searches were con-
ducted by a medical information specialist at the university medical
library in the Erasmus Medical Center.
2.2. Deﬁnitions
The majority (> 80%) of the cohort in every article had to be di-
agnosed with cancer ≤21 years of age. As we were speciﬁcally inter-
ested in ‘late’ toxicity, deﬁned as toxicity still apparent at follow-up
after end of treatment, we only included studies that evaluated meta-
bolic risk factors, bone mineral density, gonadal impairment or hearing
impairment in CCS present after end of treatment regardless of follow-
up time. Deﬁnition of endpoints used by the authors were extracted
from the corresponding papers and assembled in tables.
2.3. Study selection
Two independent investigators (EC and ALFvdK) reviewed all titles
and abstracts, and independently selected potentially eligible studies.
Case series, case reports, abstracts or reviews were excluded. Only
studies published in English were selected for the analysis.
Disagreements were resolved through consensus. Full text papers were
retrieved to assess fulﬁllment of the selection criteria (Fig. 1). Cross
reference check was performed to identify additional studies that were
potentially overlooked during the initial search. Authors were con-
tacted to clarify or supplement their results where necessary.
3. Results & discussion
The search strategy yielded 2762 unique records (Fig. 1). After
screening titles and abstracts 148 articles were selected for detailed
evaluation of full texts. For the purpose of the current review we fo-
cused on gene-association studies of metabolic syndrome, low bone
mineral density, and gonadal impairment and hearing impairment. As a
result, 27 articles were considered in this review, including seven stu-
dies on metabolic syndrome (six candidate gene studies and one
GWAS), six candidate gene studies of low bone mineral density, two
candidate gene studies of gonadal impairment, and 12 candidate gene
studies of hearing impairment (Tables 1–4).
Of the candidate gene studies, 50% (13/26) had less than 100
participants while 80% (21/26) had less than 200 participants. Only
two included a cohort of more than 500 CCS (n=532 and n=600)
(Van Waas et al., 2013; Ross et al., 2004). Only six of the candidate
studies (23%) adjusted for multiple testing to reduce the chance of type
I error (false positive results), which would take into account the
multiple models tested (Van Dorp et al., 2013; Park et al., 2016; Thiesen
et al., 2017; Brown et al., 2015; Choeyprasert et al., 2013; Ross et al.,
2009). One candidate study investigated both metabolic syndrome and
bone mineral density (Van Waas et al., 2013). Where possible, the
multivariable analysis of the combined results of the discovery and
replication cohort are reported (Tables 1–4). Where applicable, the
adjusted p-value corrected for multiple testing was reported.
3.1. Metabolic syndrome components
The prevalence of components of the metabolic syndrome, including
obesity, hypertension, dyslipidemia and type 2 diabetes (or speciﬁcally
hyperglycemia or hyperinsulinemia), has been reported to be higher in
CCS compared to the general population (Dalton et al., 2003; Rogers
et al., 2005; van Waas et al., 2010; Taskinen et al., 2000). Six candidate
gene studies and one GWAS investigated polymorphisms associated
with diﬀerent aspects of metabolic syndrome. The polymorphisms in
the candidate gene studies had been identiﬁed previously in GWASs
performed in the general population or were based on the genes coding
for hormones (or its receptor) associated with obesity. No studies ad-
dressed the genetic susceptibility of dyslipidemia. The only variants
that had been investigated in multiple independent cohorts (Table 1)
were variants within the gene coding for the leptin receptor (LEPR)
which were evaluated because of their hypothesized functional con-
tribution to obesity.
Leptin, a hormone secreted in adipocytes, has a key role in in-
creasing satiety and energy homeostasis (Allison and Myers, 2014).
Leptin insensitivity has been reported to be associated with obesity,
leading to the hypothesis that obesity in CCS may be inﬂuenced by a
carrier status of polymorphisms in the leptin receptor (LEPR) (Ross
et al., 2004). Only one (Ross et al., 2004) of the three independent
candidate gene studies in CCS that investigated the leptin pathway
found a statistically signiﬁcant correlation between a polymorphism in
LEPR (GlnQ223Arg) and higher odds of being obese (Ross et al., 2004;
Sawicka-Zkowska et al., 2013; Skoczen et al., 2011). The eﬀect was sex-
dependent and after stratiﬁcation on sex, it was only signiﬁcant in fe-
males (n=294, OR 2.5 95% CI 1.3–4.8) and not in males (n= 306). In
addition, in the female subgroup, a signiﬁcant interaction with cranial
radiation (> 20 Gy) (Ross et al., 2004) was observed, suggesting that
the impact of the polymorphism is especially prominent in female
survivors who were treated with cranial irradiation. The impact of
cranial irradiation can for a large part be attributed to the subsequent
increased risk for growth hormone deﬁciency. The association between
the GlnQ223Arg LEPR polymorphism and obesity has not been vali-
dated in the other two candidate gene studies (Sawicka-Zkowska et al.,
2013; Skoczen et al., 2011), although cranial radiotherapy did amplify
the association with leptin levels (Sawicka-Zkowska et al., 2013;
Skoczen et al., 2011). These two studies were small (77 and 74 survi-
vors, respectively) as compared to the study by Ross (600 survivors)
(Ross et al., 2004), which suggests that this inconsistency may be due to
lack of power, especially considering the possible need for stratiﬁcation
for sex, which both studies did not carry out (Sawicka-Zkowska et al.,
2013; Skoczen et al., 2011). Alternatively, this discrepancy in results
could be due to a false positive result in the initial study by Ross et al,
which did not include an independent replication cohort.
Using a candidate gene approach based on polymorphisms identi-
ﬁed in GWASs in the general population, the association of seven
polymorphisms (rs2681472, rs2681492, rs987237, rs7826222,
rs864745, rs758597, and rs2943641) with respect to hypertension,
waist circumference, diabetes and metabolic syndrome (deﬁned as
blood pressure≥ 140/90mmHg; BMI ≥30 kg/m2; self-reported pre-
valence of diabetes, or serum total cholesterol ≥5.2mmol/l) was in-
vestigated (Van Waas et al., 2013). None of these SNPs were associated
with the development of any single parameter of metabolic syndrome
among CCS (Van Waas et al., 2013), including the presence of diabetes,
and adjustment for cranial and abdominal radiotherapy did not change
these results. In contrast, cranial and abdominal radiotherapy were
strongly associated with the presence of, or components of, metabolic
syndrome. This may suggest that the impact of treatment, mainly
radiotherapy, is more dominant than the inﬂuence of the tested variants
on the components of metabolic syndrome (Van Waas et al., 2013).
The most recent genetic study was a GWAS in CCS of the St. Jude
Lifetime Cohort, performed to identify genetic variants associated with
obesity (Wilson et al., 2015). In this GWAS, the cohort was stratiﬁed on
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cranial radiation exposure. Next, 70% of the strata was used as dis-
covery cohort and 30% as replication cohort. Neither strata showed
polymorphisms in the LEPR gene to be associated with obesity (Wilson
et al., 2015). Polymorphisms in regions near or within the SOX11 and
CDH18 genes, regulators of neuronal growth, repair, and connectivity
(Haslinger et al., 2009; Hirano and Takeichi, 2012) increased the risk of
obesity among cranial radiated CCS (Wilson et al., 2015). On the other
hand, a polymorphism in FAM155A, thought to disrupt the hypotha-
lamic-pituitary axis (Wilson et al., 2015; Ge et al., 2005), decreased the
likelihood of obesity in cranial radiated CCS. These ﬁndings have not
yet been investigated in independent cohorts. Nevertheless, it is im-
portant to stress that the observed genetic variation will only partly
explain the total variation in obesity, as other environmental factors
such as cancer treatment and lifestyle are of major importance. In this
GWAS, the pseudo R2 (a measure for the amount of variability ex-
plained) in the cranial radiated strata was 0.174 for the clinical risk
factors model, and 0.303 for the clinical risk factors combined with the
SNPs model (Wilson et al., 2015). Despite a signiﬁcant increase, it also
shows that this complex human trait deserves further research to un-
derstand its pathophysiological mechanism and its genetic components.
Although a polymorphism in the LEPR gene would be a logical genetic
determinant of metabolic risk factors, the evidence to date for the as-
sociation is limited.
3.2. Gonadal impairment
Two candidate gene approach studies examined gonadal impair-
ment; one in female and one in male CCS, and neither included a re-
plication cohort.
The candidate gene study in female CCS explored the association
between genetic variation and gonadal impairment based on high or
low AMH levels (Van Dorp et al., 2013) (Table 2). Seven polymorph-
isms, each in a diﬀerent gene, were evaluated. The polymorphisms had
previously been identiﬁed in GWASs as associated with age at natural
menopause in the general population (Stolk et al., 2009; He et al.,
2010). In this study in CCS, females with a heterozygous genotype for
rs1172822 in the BRSK1 gene had higher odds of having a low AMH
value (OR=3.15, 95% CI 1.35–7.32, p=0.008). A modifying eﬀect of
the SNPs on the impact of treatment was not speciﬁcally evaluated, but
the OR was adjusted for alkylating agents score and abdominal radio-
therapy. BRSK1 is expressed in the human forebrain and to a lesser
extent in mammalian ovaries. Overexpression of the BRSK1 gene has
been hypothesized to disturb hypothalamic-pituitary-ovary axis reg-
ulation by aﬀecting the secretion of gonadotropin-releasing hormone
(GnRH) from the hypothalamus (He et al., 2009) or to inﬂuence cell-
cycle progression since it is essential for centriole duplication.
In male non-CCS, estrogen receptor deﬁciencies and polymorphisms
are associated with infertility, although the exact mechanism remains
to be elucidated (Galan et al., 2005; Ferlin et al., 2007; Guarducci et al.,
2006). The only genetic study addressing estrogen receptor poly-
morphisms in 127 CCS examined 51 SNPs. This study did not adjust for
multiple comparison and had no replication cohort, increasing the risk
of type 1 errors. Only SNPs in the estrogen receptor α gene were as-
sociated with increased risk of developing azoospermia, and this eﬀect
was stronger in the subgroup treated with high cumulative doses of
alkylating agents/cisplatin or lower doses with additional radiotherapy
(Romerius et al., 2011). Other polymorphisms, coding for androgen
receptors and estrogen receptor β, were not found to be associated with
infertility in these CCS.
In both male and female CCS only one candidate gene study has
been performed to evaluate the genetic component of variation in long-
term gonadal impairment. This variation needs further investigation,
preferably in large GWASs with a replication cohort.
3.3. Bone mineral density impairment
Genetic variation in low bone mineral density (BMD) in CCS has
been studied in six candidate gene studies (Table 3), of which one
candidate gene study included up to 100 SNPs and adjusted for multiple
comparisons (Park et al., 2016). The most recently published study (den
Hoed et al., 2016) included a replication cohort, which failed to cor-
roborate any of the earlier associations from the discovery cohort.
The CRHR1 gene has previously been found to be associated with
impaired lung function in asthma patients (Tantisira et al., 2004) and it
has been suggested that CRHR1 gene variants may also explain diﬀer-
ences in susceptibility to exogenous corticosteroid therapy, thereby
inﬂuencing lung function, but also BMD. The G allele of a poly-
morphism (rs1876828) in the CRHR1 gene was associated with lower
BMD in male survivors of acute lymphoblastic leukemia (ALL)
(p= 0.02), while, in contrast, a non-signiﬁcant higher BMD was ob-
served in female ALL survivors (p= 0.09) (Jones et al., 2008). As
previously indicated for obesity, stratiﬁcation by gender can be valu-
able, which again stresses the need for adequately sized cohorts.
Te Winkel and colleagues investigated 69 and 83 ALL survivors for
respectively two and seven polymorphisms of six candidate genes and
published this in two articles that in previous studies had shown an
association between BMD impairment in the general population
(Alvarez-Hernandez et al., 2003; Fang et al., 2003; van Rossum et al.,
2003; Lorentzon et al., 2001). ALL survivors who were carriers of the
vitamin D receptor (VDR) 5′-end haplotype 3 ha d an increased risk for
lower lumbar spine BMD (te Winkel et al., 2010). Similarly, the MTHFR
gene T-allele (rs1801133) was also identiﬁed as a risk factor for lower
total body BMD (te Winkel et al., 2011). These studies also showed that
carrier status of both VDR and MRHFR polymorphisms were associated
with low BMD at diagnosis, before any treatment had been adminis-
tered. However, the subsequent rate of BMD decline during treatment
did not diﬀer between carriers and non-carriers. Also, parameters of
body composition were not diﬀerent between carriers and non-carriers
of the MTHFR and MTRR polymorphisms at diagnosis, nor during
treatment or after treatment. This suggests that while genetic variation
may play a role in BMD variation, it does not modify the eﬀect of
treatment on BMD in ALL patients (Gjesdal et al., 2006; van Meurs
et al., 2004; Steer et al., 2009).
3.4. Hearing impairment
Hearing impairment is commonly observed after treatment of CCS
with the platinum agents cisplatin and carboplatin, or after cranial
radiation (Langer et al., 2013). The eﬀect of these treatments could be
modiﬁed by genetic polymorphisms.
Twelve candidate gene studies have been performed, none of which
included a discovery cohort larger than 250 subjects (Table 4). Only
three of the studies included an independent replication cohort and to
date, no GWAS has been published on CCS after completion of treat-
ment.
In a study by Ross et al, in 53 CCS subjects almost 2000 SNPs in 220
key pharmacogenetic genes involved in the absorption, distribution,
metabolism and elimination of drugs were genotyped. This study in-
cluded an independent replication cohort of 109 CCS. They identiﬁed
COMT and TPMT as genetic determinants of variation in hearing im-
pairment between CCS (Ross et al., 2009). Catechol O-methyl-
transferase (COMT) is involved in the metabolism of catechol drugs and
is highly expressed on hair cells of the mouse (Du et al., 2008). How-
ever, its role in auditory function remains unclear. Thiopurine S-me-
thyltransferase (TPMT), involved in the metabolism of thiopurine
drugs, has not yet been linked to cisplatin metabolism in the general
population, although it has been demonstrated in murine inner ear cells
to play a role in cisplatin metabolism and detoxiﬁcation (Bhavsar et al.,
2017; Lee et al., 2016). Four additional studies aimed to replicate the
previously identiﬁed associations of hearing impairment with COMT
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and TPMT. While one study conﬁrmed these associations (Pussegoda
et al., 2013), albeit with smaller eﬀect sizes, the other three did not
(Thiesen et al., 2017; Hagleitner et al., 2014; Yang et al., 2013). One
small study in a population of 63 children with hearing function mea-
sured during cisplatin treatment, did not detect a signiﬁcant association
of TMPT and COMT polymorphisms in children with hearing impair-
ment (Lanvers-Kaminsky et al., 2014). Despite the functional validation
of the TMPT marker in murine inner ear cells (Bhavsar et al., 2017),
uncertainty remains regarding whether COMT or TPMT polymorphisms
are genetic risk factors for hearing impairment (Lanvers-Kaminsky
et al., 2014). Lack of replication may be due to diﬀerent methods for
deﬁning hearing impairment (e.g., Brock classiﬁcation, Münster
grading system, SIOP Boston criteria, CTCAE classiﬁcation, Chang
grading), heterogeneity of the study cohorts in regards to treatment
exposure and age at diagnosis, or small sample sizes. In the study by
Yang et al, nearly all patients (91%) received the otoprotectant ami-
fostine and all had cranial radiotherapy, both of which might mask
genetic susceptibility (Yang et al., 2013). However, in their small un-
derpowered cohort of 41 survivors who did not receive amifostine or
cranial radiation, the association between TMPT and hearing impair-
ment are in line with the other studies (Ross et al., 2009; Pussegoda
et al., 2013). This highlights the importance of a homogenous popula-
tion with a large sample size, in order to avoid type 2 errors.
Polymorphisms in the low density lipoprotein-related protein 2, or
megalin (LRP2) gene, which is expressed in the marginal cells of the
stria vascularis in the inner ear, have been postulated to predispose to
cisplatin-induced hearing impairment. Three studies investigated the
association between the LRP2 gene polymorphism (rs2075252) and
hearing impairment, of which one study showed that the prevalence of
hearing impairment was higher in CCS who carried the A allele of this
polymorphism (Choeyprasert et al., 2013; Ross et al., 2009; Riedemann
et al., 2008). However, this study did not include a replication cohort.
Another variant in this gene (rs2228171) was investigated in 68 CCS
and was found to be signiﬁcant, but has not been replicated in sub-
sequent studies (Choeyprasert et al., 2013).
The association between hearing impairment and GSTT1 and GSTP1
loci, members of the glutathione S-transferases (GSTs) superfamily, was
ﬁrst described in survivors of adult cancer (Oldenburg et al., 2007).
GSTs are known to play an important role in cell protection by
scavenging free radicals caused by cisplatin by conjugating it with
glutathione (Peters et al., 2000; McIlwain et al., 2006). In CCS, the
association between cisplatin-induced hearing impairment and poly-
morphisms in the GST gene family (GSTP1, GSTT1, GSTM1, GSTM3,
GSTZ1) was investigated in four studies (Choeyprasert et al., 2013; Ross
et al., 2009; Peters et al., 2000; Rednam et al., 2013). One study of 39
survivors identiﬁed the GSTM*B allele to be associated with a lower
risk of hearing impairment (OR: 0.11, 95% CI not given, p-value: 0.02)
(Peters et al., 2000) and a larger study of 86 medulloblastoma survivors
found that survivors with the GSTP1 AG or the GG genotype had a
greater risk of hearing impairment (OR 4.0, 95% CI: 1.2–13.6,
p= 0.03) than survivors with the AA genotype (Rednam et al., 2013).
However, the latter ﬁnding may be false positive since the study by Ross
et al (Ross et al., 2009), in 162 subjects had 99.9% power to detect a
similar eﬀect at p≤ 0.05, but did not ﬁnd a signiﬁcant association
between the GSTP1 genotype and hearing impairment.
While no GWAS examining hearing impairment has been performed
in CCS after completion of therapy, one GWAS in 238 subjects reported
on susceptibility to cisplatin-induced hearing impairment measured
during childhood cancer treatment (Xu et al., 2015). Although this
study did not meet the inclusion criterion of evaluation of the late eﬀect
after end treatment –the cisplatin-related hearing loss assessment was
based on audiology data obtained between 9 and 24 months after the
initiation of therapy- it yielded valuable results for this study ﬁeld. This
study identiﬁed one signiﬁcant SNP in the ACYP2 gene (Xu et al.,
2015), which codes for an acylphosphatase that can inﬂuence Ca2+
homeostasis in the cochlea and is involved in hair cell development
(Fuchs, 2014). This ﬁnding was replicated in an independent cohort of
156 CCS after treatment, although pooling of the results from both
studies was needed to reach statistical signiﬁcance (Vos et al., 2016).
This stresses the need not only for replication in independent studies,
but also for adequately sized studies. The replication indicates there is
no diﬀerence in genetic susceptibility in the cohorts with hearing im-
pairment measured during or after treatment, which is in line with
current knowledge concerning the irreversibility of hearing impair-
ment. However, recent data suggests that in some survivors, cisplatin-
induced hearing impairment manifests later in life, suggesting that
some cases of cisplatin-induced hearing impairment might be missed if
hearing function is only measured during treatment (Clemens et al.,
2017). Up until now, no GWAS has been published to study the eﬀect of
genetic variation on hearing impairment in long-term CCS. In summary,
the following genes were associated with hearing impairment in at least
two independent sets of CCS subjects: COMT (rs4646316 and
rs9332377, ﬁve reports, two signiﬁcant (Ross et al., 2009; Pussegoda
et al., 2013)), TPMT (rs12201199, rs1142345, rs1800460, ﬁve reports,
two signiﬁcant (Ross et al., 2009; Pussegoda et al., 2013)) and ACYP2
(rs1872328, two reports, two signiﬁcant (Thiesen et al., 2017; Vos
et al., 2016)). Although large cohorts and replication cohorts are re-
quirements for solid genetic research, many studies on hearing im-
pairment do not meet these criteria. The functional signiﬁcance is not
fully understood for all SNPs and the clinical implication of poly-
morphisms in TPMT in hearing impairment has only been recently
demonstrated in murine inner ear cells (Bhavsar et al., 2017). The
functional signiﬁcance of polymorphisms in COMT in hearing impair-
ment is still unclear.
3.5. Future directions
Among childhood cancer survivors the heterogeneity of late toxi-
cities is broad, even in survivors who have been treated with the same
protocols. This suggests a role for genetic variation. However, the evi-
dence for an association between genetic variation and late toxicities
after childhood cancer is largely insuﬃcient or inconclusive to date,
with few exceptions such as the reported associations between ACYP2
and hearing impairment. The inconclusive evidence is mainly due to a
lack of well-designed, adequately powered studies. To date, in the re-
ported late eﬀects, only one GWAS has been performed. Especially in
candidate gene studies, a) cohorts are small, b) replication cohorts are
often lacking, c) the deﬁnitions used for biological endpoints are in-
consistent across studies, and d) there are diﬀerences in study design
across studies which hinders comparability. The lack of consistent as-
sociations across studies can be largely explained by methodological
factors. In addition, variations in biological factors play an important
role, since most of the outcomes studied are known to have multi-fac-
torial etiologies, which include diﬀerences in genetic background, en-
vironment, behavioral factor, as well as co-morbidity. Moreover, clin-
ical feasibility to collect data in a suﬃciently powered and
homogeneous cohort may play a role. Future research studies in this
ﬁeld could therefore beneﬁt from considering the following principles.
Firstly, future studies need to include adequately sized cohorts in
order to have suﬃcient power to identify low risk variants, which are
the expected risk variants in common traits such as the evaluated late
toxicities (i.e., common disease, common variant hypothesis). Several
studies highlight the need for stratiﬁcation or sub-analyses (Ross et al.,
2004; Jones et al., 2008), which again require larger study populations.
Power calculations and adjustment for multiple testing are essential
tools to minimize type 1 and 2 errors. GWASs are becoming more
popular and are evaluating hundreds of thousands to millions of SNP
markers at the same time and require a multiple testing adjustment to
p < 5*10−8. Therefore large sample sizes are required to achieve
suﬃcient statistical power (Hong and Park, 2012). The number of SNPs
to be included can increase exponentially when the sample size in-
creases and studies with larger sample sizes are able to detect smaller
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associations as a result of higher power (Liu and Fu, 2015). This
highlights the need for international collaboration to assure suﬃcient
sample sizes to identify genetic associations. Moreover, a large sample
size is important as the focus of genetic studies in late toxicities after
cancer often is on an interaction between treatment and a poly-
morphism, and interaction studies require even larger power than
regular association studies.
Secondly, future genetic studies will beneﬁt from inclusion of in-
dependent replication cohorts, as is common practice in the GWAS
ﬁeld, to strengthen the study design and avoid type I errors. Yet again
this needs international collaboration to replicate ﬁndings in in-
dependent studies.
Thirdly, to ensure that the genetic diﬀerence observed between
cohorts is related to the disease or condition under study and to rule-out
spurious associations, inclusion of cohorts with similar genetic back-
grounds (similar ethnicity) is preferred. For study situations, where this
is not feasible by design, several methods have been developed to
correct for ancestrally distinct populations, such as principal compo-
nents analysis, based on the variance of the studied genotypes (Price
et al., 2010). To date, most genetic studies have been performed in
Caucasians. Genetic analyses in all ethnicities are required to avoid
disparities in addressing knowledge gaps related to genetic suscept-
ibility to late treatment eﬀects.
In addition, to increase the chance of replication of results, har-
monization by consistent deﬁnitions of outcomes and evaluation of
possible confounders are necessary. Also, suﬃcient understanding of
the molecular mechanisms underlying the disease or condition is im-
portant to adequately deﬁne cases and controls. In this regard, the
proper selection of cases and controls has been extensively discussed
within genetic epidemiology (Hattersley and McCarthy, 2005).
Next, it is essential that collection, processing, storage and retrieval
of bio-specimens is conducted under quality control programs using
standard operating procedures to guarantee low inter-sample variance
and high quality of the samples. Within international collaborations,
the establishment of an international biobank could be of value.
Biobanks require high ethical practice standards, but oﬀer research and
researchers the possibility of cross-collaboration and synergy between
diﬀerent ﬁelds which is needed to further advance genetic research.
Finally, genetic technology is continuously improving, resulting in
even bigger datasets with higher genetic resolution (MacArthur et al.,
2017). Yet, the same principles as described above apply and with even
more necessity given the even larger number of genetic variants tested.
With the increasing availability of commercially available arrays and
increasing aﬀordability of large-scale GWAS, performance, coverage
and imputation quality should be considered when choosing an array.
While whole genome sequencing and whole exome sequencing have
gained considerable attention in genetic epidemiology, and are gaining
ground in the diagnostic phase of childhood cancer, none of these ap-
proaches have yet been taken in the evaluation of genetic susceptibility
to late eﬀects in CCS.
Up until now, evidence-based guidelines for CCS concerning genetic
susceptibility testing have only been developed for cardiotoxicity
(Aminkeng et al., 2016b). However, these guidelines are not im-
plemented in clinical practice yet. For other late toxicities after child-
hood cancer the currently available literature is not robust enough, as
yet, to inform reliable prediction models. However, genotyping child-
hood cancer patients in order to risk-adapt treatment based on risk
models predicting susceptibility to speciﬁc late toxicities is likely to
become standard of care. International collaboration is critical to ad-
vance knowledge of speciﬁc genetic risk factors in order to guide the
development of scientiﬁcally rigorous prediction models. Currently, we
are investigating the genetic susceptibility of hearing impairment and
female gonadal impairment in an international consortium (European
Union’s Seventh Framework programme project PanCareLIFE) with
replication planned in independent cohorts from North America
(PanCareLIFE, 2017).
4. Conclusions
With growing knowledge of genetic determinants of late-eﬀects and
the continuation in decreasing genotyping costs, more personalized
treatment protocols may become possible in the future. The criteria of
1) adequately sized cohorts and 2) the inclusion of independent re-
plication cohorts are mandatory for well-founded research in genetic
variability. International collaboration can ensure adherence to these
criteria and thus be beneﬁcial for the quality of research.
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